|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
18,750,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. Co.'s main product candidates include: INB-200, for the treatment of newly diagnosed glioblastoma, and INB-100, for the treatment of patients with high-risk leukemias that are undergoing hematopoietic stem cell transplantation. INB-400 is Co.'s first allogeneic DeltEx drug resistant immunotherapy (DeltEx DRI) product candidate to treat solid tumor cancers. INB-300 is a preclinical program focused on developing CAR-T enabled DeltEx DRI product candidates to target brain tumors and additional extracranial solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
27,300 |
4,887,459 |
| Total Buy Value |
$0 |
$0 |
$28,395 |
$9,364,623 |
| Total People Bought |
0 |
0 |
3 |
12 |
| Total Buy Transactions |
0 |
0 |
3 |
22 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ho William Tai-Wei |
President and CEO |
• • • |
2023-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
81,967 |
2,421,512 |
|
- |
|
| Rochlin Kate |
Chief Operating Officer |
• – – |
2023-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
12,295 |
17,558 |
|
- |
|
| Goswami Trishna |
Chief Medical Officer |
• – – |
2023-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
4,098 |
6,729 |
|
- |
|
| Roemer Alan S. |
Director |
– • – |
2023-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
102,459 |
158,448 |
|
- |
|
| Brandt Peter C. |
Director |
– • – |
2023-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
81,967 |
264,440 |
|
- |
|
| Mccall Patrick |
Chief Financial Officer |
• – – |
2023-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
20,492 |
26,755 |
|
- |
|
| Graff Jeremy R. |
Director |
– • – |
2023-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
2,049 |
4,549 |
|
- |
|
| Lamb Lawrence |
EVP and CSO |
• – – |
2023-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,639 |
101,369 |
|
- |
|
| Epperly Corinne |
Director |
– • – |
2023-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
81,967 |
81,967 |
|
- |
|
| Graff Jeremy R. |
Director |
– • – |
2023-09-13 |
4 |
B |
$0.95 |
$2,375 |
D/D |
2,500 |
2,500 |
2.31 |
- |
|
| Mccall Patrick |
Chief Financial Officer |
• – – |
2023-08-25 |
4 |
B |
$1.03 |
$1,030 |
D/D |
1,000 |
6,263 |
2.66 |
- |
|
| Ho William Tai-Wei |
President and CEO |
• • • |
2023-08-24 |
4 |
B |
$1.05 |
$24,990 |
D/D |
23,800 |
2,339,545 |
3.15 |
- |
|
| Fairbairn Emily |
Director |
– • – |
2023-07-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,111,958) |
0 |
|
- |
|
| Bios Advisors Gp, Llc |
Director |
– • • |
2022-12-12 |
4 |
B |
$2.48 |
$185,912 |
I/I |
75,001 |
570,724 |
2.25 |
- |
|
| Cavu Advisors, Llc |
Director |
– • • |
2022-12-12 |
4 |
B |
$2.48 |
$185,912 |
I/I |
75,001 |
570,724 |
2.25 |
- |
|
| Bios Advisors Gp, Llc |
Director |
– • • |
2022-09-28 |
4 |
B |
$2.02 |
$50,535 |
I/I |
25,000 |
561,989 |
2.25 |
- |
|
| Cavu Advisors, Llc |
Director |
– • • |
2022-09-28 |
4 |
B |
$2.02 |
$50,535 |
I/I |
25,000 |
561,989 |
2.25 |
- |
|
| Cavu Advisors, Llc |
Director |
– • • |
2022-08-29 |
4 |
B |
$2.02 |
$80,800 |
I/I |
40,000 |
559,076 |
2.25 |
- |
|
| Cavu Advisors, Llc |
Director |
– • • |
2022-08-26 |
4 |
B |
$2.01 |
$22,540 |
I/I |
11,214 |
554,416 |
2.17 |
- |
|
| Cavu Advisors, Llc |
Director |
– • • |
2022-08-17 |
4 |
B |
$1.93 |
$96,500 |
I/I |
50,000 |
553,110 |
2.25 |
- |
|
| Bios Advisors Gp, Llc |
Director |
– • • |
2022-08-17 |
4 |
B |
$1.93 |
$96,500 |
I/I |
50,000 |
553,110 |
2.25 |
- |
|
| Ho William Tai-Wei |
President, CEO and CFO |
• • – |
2022-08-16 |
4 |
B |
$1.90 |
$49,999 |
D/D |
26,315 |
2,315,745 |
2.81 |
- |
|
| Roemer Alan S. |
Director |
– • – |
2022-08-16 |
4 |
B |
$1.90 |
$49,999 |
D/D |
26,315 |
55,989 |
2.39 |
- |
|
| Mccall Patrick |
Chief Financial Officer |
• – – |
2022-08-16 |
4 |
B |
$1.90 |
$10,000 |
D/D |
5,263 |
5,263 |
2.74 |
- |
|
| Greenwood Luba |
Director |
– • – |
2022-08-16 |
4 |
B |
$1.90 |
$999 |
D/D |
526 |
7,826 |
2.31 |
- |
|
38 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
